Effect of Sacubitril Valsartan on Cardiac Function and Inflammatory Factors in Patients with Heart Failure with Preserved Ejection Frac-tion
Objectives To explore the effect of conventional therapy combined with Sacubitril Valsartan on cardiac function and inflammatory factors in patients with heart failure with preserved ejection fraction.Methods A total of 62 patients with heart failure with preserved ejection fraction admitted to our hospital from January 2020 to March 2023 were selected and divided into control group and observation group randomly,with 31 cases in each group.The control group was given routine treatment,and the observation group was treated with Sacubitril Valsartan on the basis of routine treatment.The cardiac function,inflammatory factors and quality of life before and after treat-ment were compared between the two groups,and the efficacy and adverse reactions were also compared between the two groups.Results The total effective rate of the observation group was 96.77%,which was significantly high-er than the 80.65%in the control group(P＜0.05).After treatment,the 6MWT of the two groups was longer than that before treatment,and the 6MWT in the observation group was longer than that in the control group.The levels of HR and LVESD in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group.The levels of LVEF in the two groups were higher than those before treatment,and that in the observation group was higher than that in the control group.The difference was statistical-ly significant(P＜0.05).After treatment,the levels of serum TNF-α,IL-6 and hs-CRP in the two groups were signif-icantly lower than those before treatment,and those in the observation group were significantly lower than those in the control group(P＜0.05).After treatment,the scores of social,psychological and physical function and material life in the two groups were significantly higher than those before treatment,and those in the observation group were sig-nificantly higher than those in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 6.45%,which was significantly lower than the 25.81%in the control group(P＜0.05).Conclusions Sacu-bitril Valsartan can inhibit the production of inflammatory factors in patients with heart failure with preserved ejec-tion fraction.It can also protect cardiac function,improve efficacy and quality of life,and reduce the incidence of adverse reactions.
万方数据
维普
